PDCD1 and gastric cancer: Currently, checkpoint pathway blockades of PD1/PD-L1 have been a highly promising immunotherapy by activating T lymphocytes and enhancing antitumor immunity, thus leading to an impressive outcome in patients with gastric cancer [16,17,18,19].